Insulin micro-secretion in Type 1 diabetes and related microRNA profiles
Abstract The aim of this cross-sectional study was to compare plasma C-peptide presence and levels in people without diabetes (CON) and with Type 1 diabetes and relate C-peptide status to clinical factors. In a subset we evaluated 50 microRNAs (miRs) previously implicated in beta-cell death and asso...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-90856-6 |
id |
doaj-b1ec56fdb12a4c0cb5cb32be78d2f006 |
---|---|
record_format |
Article |
spelling |
doaj-b1ec56fdb12a4c0cb5cb32be78d2f0062021-06-06T11:37:42ZengNature Publishing GroupScientific Reports2045-23222021-06-0111111110.1038/s41598-021-90856-6Insulin micro-secretion in Type 1 diabetes and related microRNA profilesAndrzej S. Januszewski0Yoon Hi Cho1Mugdha V. Joglekar2Ryan J. Farr3Emma S. Scott4Wilson K. M. Wong5Luke M. Carroll6Yik W. Loh7Paul Z. Benitez-Aguirre8Anthony C. Keech9David N. O’Neal10Maria E. Craig11Anandwardhan A. Hardikar12Kim C. Donaghue13Alicia J. Jenkins14NHMRC Clinical Trials Centre, University of SydneyDiscipline of Paediatrics and Child Health, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyDiscipline of Paediatrics and Child Health, University of SydneyNHMRC Clinical Trials Centre, University of SydneyDepartment of Medicine, University of MelbourneDiscipline of Paediatrics and Child Health, University of SydneyNHMRC Clinical Trials Centre, University of SydneyDiscipline of Paediatrics and Child Health, University of SydneyNHMRC Clinical Trials Centre, University of SydneyAbstract The aim of this cross-sectional study was to compare plasma C-peptide presence and levels in people without diabetes (CON) and with Type 1 diabetes and relate C-peptide status to clinical factors. In a subset we evaluated 50 microRNAs (miRs) previously implicated in beta-cell death and associations with clinical status and C-peptide levels. Diabetes age of onset was stratified as adult (≥ 18 y.o) or childhood (< 18 y.o.), and diabetes duration was stratified as ≤ 10 years, 10–20 years and > 20 years. Plasma C-peptide was measured by ultrasensitive ELISA. Plasma miRs were quantified using TaqMan probe-primer mix on an OpenArray platform. C-peptide was detectable in 55.3% of (n = 349) people with diabetes, including 64.1% of adults and 34.0% of youth with diabetes, p < 0.0001 and in all (n = 253) participants without diabetes (CON). C-peptide levels, when detectable, were lower in the individuals with diabetes than in the CON group [median lower quartile (LQ)–upper quartile (UQ)] 5.0 (2.6–28.7) versus 650.9 (401.2–732.4) pmol/L respectively, p < 0.0001 and lower in childhood versus adult-onset diabetes [median (LQ–UQ) 4.2 (2.6–12.2) pmol/L vs. 8.0 (2.3–80.5) pmol/L, p = 0.02, respectively]. In the childhood-onset group more people with longer diabetes duration (> 20 years) had detectable C-peptide (60%) than in those with shorter diabetes duration (39%, p for trend < 0.05). Nine miRs significantly correlated with detectable C-peptide levels in people with diabetes and 16 miRs correlated with C-peptide levels in CON. Our cross-sectional study results are supportive of (a) greater beta-cell function loss in younger onset Type 1 diabetes; (b) persistent insulin secretion in adult-onset diabetes and possibly regenerative secretion in childhood-onset long diabetes duration; and (c) relationships of C-peptide levels with circulating miRs. Confirmatory clinical studies and related basic science studies are merited.https://doi.org/10.1038/s41598-021-90856-6 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andrzej S. Januszewski Yoon Hi Cho Mugdha V. Joglekar Ryan J. Farr Emma S. Scott Wilson K. M. Wong Luke M. Carroll Yik W. Loh Paul Z. Benitez-Aguirre Anthony C. Keech David N. O’Neal Maria E. Craig Anandwardhan A. Hardikar Kim C. Donaghue Alicia J. Jenkins |
spellingShingle |
Andrzej S. Januszewski Yoon Hi Cho Mugdha V. Joglekar Ryan J. Farr Emma S. Scott Wilson K. M. Wong Luke M. Carroll Yik W. Loh Paul Z. Benitez-Aguirre Anthony C. Keech David N. O’Neal Maria E. Craig Anandwardhan A. Hardikar Kim C. Donaghue Alicia J. Jenkins Insulin micro-secretion in Type 1 diabetes and related microRNA profiles Scientific Reports |
author_facet |
Andrzej S. Januszewski Yoon Hi Cho Mugdha V. Joglekar Ryan J. Farr Emma S. Scott Wilson K. M. Wong Luke M. Carroll Yik W. Loh Paul Z. Benitez-Aguirre Anthony C. Keech David N. O’Neal Maria E. Craig Anandwardhan A. Hardikar Kim C. Donaghue Alicia J. Jenkins |
author_sort |
Andrzej S. Januszewski |
title |
Insulin micro-secretion in Type 1 diabetes and related microRNA profiles |
title_short |
Insulin micro-secretion in Type 1 diabetes and related microRNA profiles |
title_full |
Insulin micro-secretion in Type 1 diabetes and related microRNA profiles |
title_fullStr |
Insulin micro-secretion in Type 1 diabetes and related microRNA profiles |
title_full_unstemmed |
Insulin micro-secretion in Type 1 diabetes and related microRNA profiles |
title_sort |
insulin micro-secretion in type 1 diabetes and related microrna profiles |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2021-06-01 |
description |
Abstract The aim of this cross-sectional study was to compare plasma C-peptide presence and levels in people without diabetes (CON) and with Type 1 diabetes and relate C-peptide status to clinical factors. In a subset we evaluated 50 microRNAs (miRs) previously implicated in beta-cell death and associations with clinical status and C-peptide levels. Diabetes age of onset was stratified as adult (≥ 18 y.o) or childhood (< 18 y.o.), and diabetes duration was stratified as ≤ 10 years, 10–20 years and > 20 years. Plasma C-peptide was measured by ultrasensitive ELISA. Plasma miRs were quantified using TaqMan probe-primer mix on an OpenArray platform. C-peptide was detectable in 55.3% of (n = 349) people with diabetes, including 64.1% of adults and 34.0% of youth with diabetes, p < 0.0001 and in all (n = 253) participants without diabetes (CON). C-peptide levels, when detectable, were lower in the individuals with diabetes than in the CON group [median lower quartile (LQ)–upper quartile (UQ)] 5.0 (2.6–28.7) versus 650.9 (401.2–732.4) pmol/L respectively, p < 0.0001 and lower in childhood versus adult-onset diabetes [median (LQ–UQ) 4.2 (2.6–12.2) pmol/L vs. 8.0 (2.3–80.5) pmol/L, p = 0.02, respectively]. In the childhood-onset group more people with longer diabetes duration (> 20 years) had detectable C-peptide (60%) than in those with shorter diabetes duration (39%, p for trend < 0.05). Nine miRs significantly correlated with detectable C-peptide levels in people with diabetes and 16 miRs correlated with C-peptide levels in CON. Our cross-sectional study results are supportive of (a) greater beta-cell function loss in younger onset Type 1 diabetes; (b) persistent insulin secretion in adult-onset diabetes and possibly regenerative secretion in childhood-onset long diabetes duration; and (c) relationships of C-peptide levels with circulating miRs. Confirmatory clinical studies and related basic science studies are merited. |
url |
https://doi.org/10.1038/s41598-021-90856-6 |
work_keys_str_mv |
AT andrzejsjanuszewski insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT yoonhicho insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT mugdhavjoglekar insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT ryanjfarr insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT emmasscott insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT wilsonkmwong insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT lukemcarroll insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT yikwloh insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT paulzbenitezaguirre insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT anthonyckeech insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT davidnoneal insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT mariaecraig insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT anandwardhanahardikar insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT kimcdonaghue insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles AT aliciajjenkins insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles |
_version_ |
1721393871686991872 |